Outlook Therapeutics (OTLK) Competitors $1.57 +0.01 (+0.64%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. CRDF, IVA, FULC, BTMD, SOPH, GOSS, ANNX, HURA, DBVT, and PRMEShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Cardiff Oncology (CRDF), Inventiva (IVA), Fulcrum Therapeutics (FULC), biote (BTMD), SOPHiA GENETICS (SOPH), Gossamer Bio (GOSS), Annexon (ANNX), TuHURA Biosciences (HURA), DBV Technologies (DBVT), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. Cardiff Oncology Inventiva Fulcrum Therapeutics biote SOPHiA GENETICS Gossamer Bio Annexon TuHURA Biosciences DBV Technologies Prime Medicine Outlook Therapeutics (NASDAQ:OTLK) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts rate OTLK or CRDF? Outlook Therapeutics presently has a consensus price target of $10.20, indicating a potential upside of 553.85%. Cardiff Oncology has a consensus price target of $11.67, indicating a potential upside of 319.66%. Given Outlook Therapeutics' higher probable upside, research analysts clearly believe Outlook Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in OTLK or CRDF? Outlook Therapeutics received 123 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 71.12% of users gave Outlook Therapeutics an outperform vote while only 64.62% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% Cardiff OncologyOutperform Votes4264.62% Underperform Votes2335.38% Does the media prefer OTLK or CRDF? In the previous week, Cardiff Oncology had 3 more articles in the media than Outlook Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 1 mentions for Outlook Therapeutics. Outlook Therapeutics' average media sentiment score of 1.89 beat Cardiff Oncology's score of 1.06 indicating that Outlook Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Outlook Therapeutics Very Positive Cardiff Oncology Positive Which has more volatility and risk, OTLK or CRDF? Outlook Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Is OTLK or CRDF more profitable? Outlook Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Outlook Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -225.12% Cardiff Oncology -6,238.17%-73.97%-60.40% Which has stronger earnings & valuation, OTLK or CRDF? Cardiff Oncology has higher revenue and earnings than Outlook Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$75.37M-$7.42-0.21Cardiff Oncology$683K270.77-$41.44M-$0.94-2.96 Do institutionals & insiders hold more shares of OTLK or CRDF? 11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 4.8% of Outlook Therapeutics shares are held by insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryCardiff Oncology beats Outlook Therapeutics on 9 of the 17 factors compared between the two stocks. Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.95M$2.96B$5.52B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.2129.8222.4418.53Price / SalesN/A492.56394.20103.32Price / CashN/A168.6838.1834.62Price / Book-0.993.196.744.24Net Income-$75.37M-$72.17M$3.22B$248.05M7 Day Performance0.65%1.48%2.37%3.17%1 Month Performance18.18%-1.82%-0.86%1.68%1 Year Performance-82.51%-22.14%17.84%5.93% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics1.8423 of 5 stars$1.57+0.6%$10.20+549.7%-82.9%$50.27MN/A-0.2120Positive NewsCRDFCardiff Oncology1.441 of 5 stars$2.82-1.1%$11.67+313.7%-37.7%$187.60M$683,000.00-3.0020Upcoming EarningsIVAInventiva1.9446 of 5 stars$3.56+6.0%$10.40+192.1%+18.9%$186.82M$9.20M0.00100Gap DownFULCFulcrum Therapeutics2.0058 of 5 stars$3.46+5.2%$8.63+149.3%-48.4%$186.77M$80M-11.16100Positive NewsBTMDbiote3.8198 of 5 stars$3.41+3.3%$8.00+134.6%-35.4%$186.56M$197.19M13.12194Upcoming EarningsPositive NewsSOPHSOPHiA GENETICS2.3619 of 5 stars$2.78-1.8%$6.80+144.6%-37.5%$185.39M$65.17M-2.55520Upcoming EarningsNews CoverageGOSSGossamer Bio3.9639 of 5 stars$0.81-3.5%$7.50+822.5%+26.6%$184.73M$114.70M-2.54180Upcoming EarningsNews CoveragePositive NewsANNXAnnexon2.0276 of 5 stars$1.68+15.1%$18.67+1,011.1%-59.6%$184.31MN/A-1.6060Positive NewsHURATuHURA BiosciencesN/A$4.20+1.2%$12.67+201.6%N/A$183.46MN/A0.00N/APositive NewsDBVTDBV Technologies3.6442 of 5 stars$8.91+11.7%$22.50+152.5%+31.4%$183.30M$15.73M-1.9880Upcoming EarningsShort Interest ↓News CoveragePositive NewsPRMEPrime Medicine2.4136 of 5 stars$1.39+12.1%$13.38+862.2%-67.1%$182.31M$2.98M-0.68234Gap DownHigh Trading Volume Related Companies and Tools Related Companies Cardiff Oncology Competitors Inventiva Competitors Fulcrum Therapeutics Competitors biote Competitors SOPHiA GENETICS Competitors Gossamer Bio Competitors Annexon Competitors TuHURA Biosciences Competitors DBV Technologies Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredYou’re About to Lose Everything – Act Now or Regret It ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
